ArticlePsychopharmacology2010
The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder.
Article in Psychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.Drug design, development and therapy · 2015Pooled it
- Trial
- Trial
- The effect of adjuvant treatment in obsessive compulsive disorder patients: A systematic review and meta-analysis.Journal of family medicine and primary care · 2025Article
- Ketogenic Diet as a Nutritional Metabolic Intervention for Obsessive-Compulsive Disorder: A Narrative Review.Nutrients · 2024Review
- Drugs with glutamate-based mechanisms of action in psychiatry.Pharmacological reports : PR · 2024Review
- Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder.Brain sciences · 2022Article
- Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?World journal of psychiatry · 2021Review
- The hippocampus encodes delay and value information during delay-discounting decision making.eLife · 2020Article
- Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives.Neuropsychiatric disease and treatment · 2020Review
- Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia.Frontiers in behavioral neuroscience · 2019Article
- Signal attenuation as a rat model of obsessive compulsive disorder.Journal of visualized experiments : JoVE · 2015Article
- Animal models of obsessive-compulsive disorder: utility and limitations.Neuropsychiatric disease and treatment · 2015Review
- A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.Psychology research and behavior management · 2015Review
- Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.Advances in medicine · 2014Review
- The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder.Psychopharmacology · 2013Article
- Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.Frontiers in pharmacology · 2013Article
- The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.Pharmacology, biochemistry, and behavior · 2012Review
- Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.Pharmacology & therapeutics · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleIn recent years, an increasing body of evidence points to the involvement of the glutamatergic system and specifically the glutamatergic ionotropic N-methyl-D-aspartate (NMDA) receptor in the pathophysiology of obsessive-compulsive disorder (OCD).
objectivesTo test the role of NMDA receptors in compulsive behavior using the signal attenuation rat model of OCD. In this model, 'compulsive' behavior is induced by attenuating a signal indicating that a lever-press response was effective in producing food.
methodsThe NMDA antagonist, MK 801 (0.025-0.100 mg/kg) and the partial NMDA agonist, D-cycloserine (3-100 mg/kg) were administered to rats just before assessing their lever-press responding following signal attenuation (Experiments 1 and 2, respectively). Because the effects of signal attenuation are assessed under extinction conditions, drug doses that were effective in Experiments 1 and 2 were also tested in an extinction session of lever-press responding that was not preceded by signal attenuation (Experiment 3).
resultsSystemic administration of D: -cycloserine (15 mg/kg) selectively decreased compulsive lever pressing, whereas systemic administration of MK 801 did not affect compulsive lever-pressing but dramatically increased resistance to extinction.
conclusionsActivation of NMDA receptors may have an anti-compulsive effect in OCD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.